Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

97 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-10

Study Completion Date

2020-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The antifungal efficacy and safety of Jublia® topical solution will be assessed through an administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due to dermatophyte.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating the Effect of Jublia on Dermatophytomas

NCT03098615

Onychomycosis Dermatophytosis

COMPLETED PHASE4

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

NCT00453271

Onychomycosis

COMPLETED PHASE2

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02859519

Distal Subungual Onychomycosis

COMPLETED PHASE3

An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

NCT01814020

Distal Subungual Onychomycosis

COMPLETED PHASE2

Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish

NCT03110029

Onychomycosis of Toenail

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluate anti-fungal activity and safety of efinaconazole in patients with mild to moderate toenail onychomycosis caused by dermatophytes that received a 48-week administration of efinaconazole.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild to Moderate Onychomycosis Due to Dermatophyte

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Jublia®

Group Type EXPERIMENTAL

Jublia®

Intervention Type DRUG

Jublia® topical solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Jublia®

Jublia® topical solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult male and female subjects of ages in the range over 19.
* The subjects diagnosed with onychomycosis in up to 6 toenails at least

1 great toenail woth no fingernails
* The subjects diagnosed with a mild to moderate onychomycosis (20% to 50% of surface of target nail without nail matrix infection or dermatophytoma)
* The subjects having target nails less than 3mm in thickness and over 3mm in length
* Positive indication on KOH Direct Microscopic Inspection on target nail
* Positive dermatophyte or dermatophyte/candida on Fungi Cultivation Inspection on target nail
* The subjects completely understood the clinical trial through detailed explanation presented, determined to participate in the clinical trial spontaneously, and agreed to observe precautions suggested thereby through written consent.

Exclusion Criteria

* The subjects suffering other diseases that may cause nail abnormalities or are supposed to be affecting the assessment of the efficacy of study agent by the judgment of investigators
* The subjects having a case history of hypersensitivity reaction to the component of Jublia® topical solution or Azole derivatives.
* The pregnant, lactating, or fertile woman free from pertinent contraception

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No